Low-density lipoprotein triglyceride predicts outcomes in patients with chronic coronary syndrome following percutaneous coronary intervention according to inflammatory status

Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease

(2020) Rishi Puri et al.   JAMA Cardiology

The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials

(2020) Nicholas H Adamstein et al.   EUROPEAN HEART JOURNAL

C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left Main coronary artery disease: Analysis from the EXCEL trial

(2019) Ioanna Kosmidou et al.   AMERICAN HEART JOURNAL

Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention

(2019) Paul Guedeney et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical Significance of High-Sensitivity C-Reactive Protein in Patients with Preserved Renal Function Following Percutaneous Coronary Intervention

(2019) Takashi Shimizu et al.   International Heart Journal

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

(2019) Jean-Claude Tardif et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammatory and Cholesterol Risk in the FOURIER Trial

(2018) Erin A. Bohula et al.   CIRCULATION

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy

(2018) Aruna D. Pradhan et al.   CIRCULATION

Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease

(2018) Anum Saeed et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Low-Density Lipoprotein Triglycerides

(2018) Michael Miller   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

(2018) Paul M Ridker et al.   LANCET

OUP accepted manuscript

(2018)   EUROPEAN HEART JOURNAL

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

(2018) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease

(2016) Anette Varbo et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial

(2016) John J. Albers et al.   ATHEROSCLEROSIS

From C-Reactive Protein to Interleukin-6 to Interleukin-1

(2016) Paul M Ridker   CIRCULATION RESEARCH

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

(2016) Paul M Ridker   EUROPEAN HEART JOURNAL

High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention

(2016) Rohit M. Oemrawsingh et al.   EuroIntervention

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-ITCLINICAL PERSPECTIVES

(2015) Erin A. Bohula et al.   CIRCULATION

Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease

(2012) Anette Varbo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention

(2011) Jaroslav Hubacek et al.   CANADIAN JOURNAL OF CARDIOLOGY

C-Reactive Protein and the Risk of Stent Thrombosis and Cardiovascular Events After Drug-Eluting Stent Implantation

(2009) Duk-Woo Park et al.   CIRCULATION

Inflammation in Atherosclerosis

(2009) Peter Libby et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY